LivaNova (LIVN) Receivables - Other (2017 - 2026)
LivaNova (LIVN) posted Receivables - Other of $600000.0 for Q4 2025, down 93.75% sequentially from $9.6 million in Q2 2025, and down 81.82% YoY from $3.3 million in Q4 2024.
LivaNova (LIVN) Receivables - Other (2017 - 2026) Analysis & Trends
LivaNova has reported Receivables - Other for 3 years, with the latest figure at $600000.0 in Q4 2025.
- Quarterly Receivables - Other fell 81.82% year-over-year to $600000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $600000.0 (down 81.82% YoY) and the FY2025 annual result came in at $600000.0, down 88.24% from the prior year.
- Receivables - Other declined to $600000.0 in Q4 2025 per LIVN's latest filing, from $9.6 million in the prior quarter.
- Over five years, Receivables - Other peaked at $9.6 million in Q2 2025 and troughed at $100000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.11 Bn | 194.51 Bn | 7.27 Bn |
| 2 | Stryker | 129.85 Bn | 126.37 Bn | 4.50 Bn |
| 3 | Medtronic | 119.93 Bn | 110.71 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.18 Bn | 73.64 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.54 Bn | 48.29 Bn | 1.35 Bn |
| 6 | Dexcom | 34.76 Bn | 32.81 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.25 Bn | 32.14 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn |
| 9 | Steris | 23.29 Bn | 22.80 Bn | 684.20 Mn |
| 10 | LivaNova | 4.33 Bn | 3.81 Bn | 273.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.90 Mn |
| Jun 30, 2026 | 14.90 Mn |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Jun 30, 2025 | 9.60 Mn |
| Jun 30, 2025 | 9.60 Mn |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 3.30 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Sep 30, 2017 | 4.36 Mn |
| Sep 30, 2017 | 4.36 Mn |